FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.
Page 34 of 34
Jan 6, 2026The number of recommended childhood vaccinations has been significantly trimmed, raising concerns among health experts about the new vaccine schedule's impact on children's near- and long-term health. This major policy change alters the longstanding immunization framework.
TCB Team
Jan 6, 2026In an effort to encourage innovation and adoption of digital health products, the FDA will reduce regulatory burdens on wearables and AI-powered devices, marking a strategic departure from past stringent oversight.
TCB Team
Jan 6, 2026Despite repeated extensions of telehealth prescribing flexibilities by the DEA and other agencies, uncertainty remains. The AMA advocates for permanent legislative action to ensure stable patient access and provider reimbursement for telehealth services.
TCB Team
Jan 6, 2026Sanofi's experimental oral BTK inhibitor tolebrutinib, intended for multiple sclerosis treatment, hit a regulatory setback with the FDA last month. The agency's detailed refusal highlights ongoing challenges in balancing drug safety and therapeutic proof in neuroimmune diseases.
TCB TeamMachine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.